Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy

• Published in: American journal of hematology 2017-12, Vol.92 (12), p.1280-1286
• Main Authors: Cho, Hyungwoo, Yoon, Dok Hyun, Lee, Jung Bok, Kim, Sung‐Yong, Moon, Joon Ho, Do, Young Rok, Lee, Jae Hoon, Park, Yong, Lee, Ho Sup, Eom, Hyeon Seok, Shin, Ho‐Jin, Min, Chang‐Ki, Kim, Jin Seok, Jo, Jae‐Cheol, Kang, Hye Jin, Mun, Yeung‐Chul, Lee, Won Sik, Lee, Je‐Jung, Suh, Cheolwon, Kim, Kihyun
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Bortezomib; Bortezomib - therapeutic use; Female; Hematology; Humans; Male; Middle Aged; Models, Statistical; Multiple myeloma; Multiple Myeloma - diagnosis; Multiple Myeloma - drug therapy; Multiple Myeloma - mortality; Neoplasm Staging - standards; Protease inhibitors; Retrospective Studies; Risk Assessment; ROC Curve; Survival Rate; Thalidomide; Thalidomide - analogs & derivatives; Thalidomide - therapeutic use
• ISSN: 0361-8609; 1096-8652
• DOI: 10.1002/ajh.24891

The revised International Staging System (R‐ISS) has recently been developed to improve the risk stratification of multiple myeloma (MM) patients over the ISS. We assessed the R‐ISS in MM patients who were treated with novel agents as a primary therapy and evaluated its discriminative power and ability to reclassify patients from the ISS. A total of 514 newly diagnosed MM patients treated with novel agents including thalidomide, bortezomib, and lenalidomide as a primary therapy were included in this retrospective analysis. With a median follow‐up duration of 42.3 months (range, 40.5–44.1), the median overall survival (OS) was 61.0 months. There was a significant difference in median OS (not reached, 60.9, and 50.1 months for stages 1, 2, and 3, respectively, P